{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:22:06Z","timestamp":1777432926143,"version":"3.51.4"},"reference-count":7,"publisher":"American Association for Cancer Research (AACR)","issue":"6","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Summary:<\/jats:title>\n                  <jats:p>IL2 is a type I cytokine that is associated, when given at high doses intravenously, with durable regressionin a subset of patients with metastatic melanoma and renal cell carcinoma, yet high toxicity limits its use. NKTR-214 is a novel pegylated IL2 with minor clinical activity as a single agent, but a favorable toxicity profile and compelling pharmacodynamic effects that predict utility in combination with immune checkpoint inhibition.<\/jats:p>\n                  <jats:p>See related article by Bentebibel et al., p. 711.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-19-0412","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T12:35:32Z","timestamp":1559565332000},"page":"694-695","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Back to the Future: Rethinking and Retooling IL2 in the Immune Checkpoint Inhibitor Era"],"prefix":"10.1158","volume":"9","author":[{"given":"Ryan J.","family":"Sullivan","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2019,6,3]]},"reference":[{"key":"2022060702030129500_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","article-title":"Interleukin-2 receptor signaling: at the interface between tolerance and immunity","volume":"33","author":"Malek","year":"2010","journal-title":"Immunity"},{"key":"2022060702030129500_bib2","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"2022060702030129500_bib3","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"2022060702030129500_bib4","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.1994.12.8.1572","article-title":"Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report","volume":"12","author":"Yang","year":"1994","journal-title":"J Clin Oncol"},{"key":"2022060702030129500_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40425-018-0362-6","article-title":"An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0","volume":"6","author":"Sullivan","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2022060702030129500_bib6","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-18-1495","article-title":"A first-in-human study and biomarker analysis of NKTR-214, a novel IL2R\u03b2\u03b3-biased cytokine, in patients with advanced or metastatic solid tumors","author":"Bentebibel","year":"2019","journal-title":"Cancer Discov"},{"key":"2022060702030129500_bib7","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/9\/6\/694\/1728925\/694.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/9\/6\/694\/1728925\/694.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T02:03:14Z","timestamp":1654567394000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/9\/6\/694\/42162\/Back-to-the-Future-Rethinking-and-Retooling-IL2-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":7,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6,3]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-19-0412","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}